Scottish Consortium TMaT Programme: 'Characterising the development of chemotherapy induced peripheral neuropathy (CIPN) and assessing a novel TRPM8 agonist treatment, using functional magnetic imaging resonance (fMRI)'. (360G-Wellcome-099440_Z_12_Z)

We propose a first-class training programme to create a cadre of clinical academics withoutstanding TMT capabilities [Glossary:Annex-A], building on an established collaboration among internationally competitive scientists within four Scottish clinical academic institutions and a leading global pharmaceutical company, Wyeth (TMRC, value ~£50million). STMTI will focus initially on translational approaches to disorders of high priority in which considerable unmet clinical need remains, and where there is compelling opportunity for ‘pathogenesis-to-clinic’ transition. Thus, cardiovascular/metabolic, inflammation, musculoskeletal, neuroscience and reproductive health themes are proposed [Annex-B]. STMTI builds on a well-established collaboration among academia, industry, NHS and government, combining complementary strengths in drug discovery and the various stages of drug development. Critically, all relevant enabling tools – bioinformatics, genetics, proteomics, imaging, biomarker development and high- quality phenotyping – are available. STMTI employs established, well-developed and nationally networked clinical research facilities, and an associated Scottish-wide research education programme. STMTI thereby creates an innovative interdisciplinary TMT training programme that will allow seamless academic career progression for outstanding clinicians: from MSc certification to clinical PhD training, and onwards to academically-protected clinical lectureships. STMTI will place its fellows in an enviable and highly competitive position for a career in TMT and ultimate appointment to senior academic positions.